GlassScriptPhysician profile
Emily E Gale
NPI 1740809250
$4,083.37
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $355 · 2022: $1,038 · 2023: $1,824 · 2024: $866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,690.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,138.67 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $381.61 | 2023-2024 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $369.17 | 2021-2024 | Dupixent |
| Ucb, INC. | $338.51 | 2021-2024 | Bimzelx, Cimzia |
| Lilly USA, LLC | $283.31 | 2021-2024 | Taltz, Olumiant |
| Journey Medical Corporation | $255.65 | 2022 | |
| Sun Pharmaceutical Industries INC. | $219.51 | 2022-2024 | Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $192.63 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $150.01 | 2021-2024 | Jublia, Cabtreo |
| Pfizer INC. | $124.57 | 2021-2023 | |
| Genzyme Corporation | $94.68 | 2021-2024 | |
| Incyte Corporation | $83.41 | 2022-2023 | Opzelura |
| Leo Pharma INC. | $76.56 | 2022-2024 | Adbry |
| Amgen INC. | $75.03 | 2023 | Otezla |
| Novartis Pharmaceuticals Corporation | $57.26 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $54.99 | 2022 | |
| Galderma Laboratories, L.P. | $42.98 | 2022-2023 | |
| Mayne Pharma Commercial LLC | $38.55 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $29.21 | 2024 | Valchlor |
| Verrica Pharmaceuticals INC. | $22.10 | 2023 | Ycanth |
| Biofrontera INC. | $19.64 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $18.87 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.45 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Gale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.